Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary highlights a lack of revenue and increasing net losses, which are negative indicators. The company's operational updates and return plans were not discussed, adding uncertainty. The forward-looking statements emphasize potential risks, and the Q&A section offered no additional clarity. Although the company has sufficient funding until 2029, the increase in R&D and G&A expenses without revenue generation contributes to a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Revenue No revenue reported for the quarter as the company is still in the development stage.
Net Loss Net loss for Q1 2026 was $25.3 million, an increase of 15% year-over-year due to higher R&D expenses.
Research and Development (R&D) Expenses R&D expenses increased to $18.7 million, up 20% year-over-year, driven by expanded clinical trial activities.
General and Administrative (G&A) Expenses G&A expenses were $6.1 million, a 10% increase year-over-year, attributed to higher personnel costs and professional fees.
Cash and Cash Equivalents Cash and cash equivalents were $45.2 million as of March 31, 2026, compared to $50.5 million as of December 31, 2025, reflecting operational cash burn.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges that actual results could differ materially from forward-looking statements due to risks and uncertainties associated with its business.
Time-sensitive information: The information shared during the call is accurate only as of the date of the broadcast, indicating potential risks if decisions are based on outdated information.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: Relmada issued a press release providing a business update and outlining its financial results for the 3 months ended March 31, 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors LLC
Brian LifeSci
Brian Lifesci
CEO Director
Capital Markets
Co Research
Director Raj
Division Ear
Division Farzin
Division Liu
Division PM
EDT afternoon
Farzin Haque
Goodwin Piper
Haque Jefferies
Jefferies LLC
Kelsey Goodwin
LLC Kelsey
LLC Research
Liu Lucid
Lucid Capital
Maged Shenouda
Mr conference
Officer Brian
PM EDT
Piper Sandler
Pruthi Chief
Raj Pruthi
Research Division
Sandler Co
Sergio Traversa
Urology Maged
website Brian
RLMD Transcript
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call summary highlights a lack of revenue and increasing net losses, which are negative indicators. The company's operational updates and return plans were not discussed, adding uncertainty. The forward-looking statements emphasize potential risks, and the Q&A section offered no additional clarity. Although the company has sufficient funding until 2029, the increase in R&D and G&A expenses without revenue generation contributes to a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Relmada Therapeutics, Inc. (RLMD) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call presents a mixed picture: strong financial backing and strategic plans for NDV-01 and sepranolone, but with notable risks in supply chain and financial management. The Q&A section highlights uncertainties, particularly regarding compliance with FDA requirements and market adoption challenges. Despite a positive cash position and reduced R&D expenses, the increase in net loss and operational costs raises concerns. The lack of clear guidance on FDA expectations and market strategy tempers enthusiasm, leading to a neutral stock price prediction.
Relmada Therapeutics, Inc. (RLMD) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance shows reduced losses and expenses, which is positive, but cash reserves are dwindling. Product development updates and strategic plans seem promising, but are contingent on future FDA approvals and trial outcomes, posing significant risks. The Q&A session reveals potential market opportunities but lacks clarity on pricing strategies and timelines. Overall, the sentiment is neutral, as the positive aspects are balanced by uncertainties and risks, particularly in regulatory and market adoption areas.
Relmada Therapeutics, Inc. (RLMD) Q2 2025 Earnings Call Transcript
Unknown8-8
Despite promising product developments and reduced losses, Relmada's high cash burn rate, decreased cash reserves, and looming financial sustainability issues pose significant risks. The Q&A highlights uncertainties in regulatory pathways and market strategies, with potential delays in trials and increased competition. The company's financial situation is precarious, with limited cash to support future R&D activities. Without a clear path to additional financing or significant revenue, the stock is likely to experience negative sentiment, especially in the absence of a market cap to buffer volatility.
RLMD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
